Zimbabwe has declined a substantial American health deal valued at 367 million US dollars (272 million pounds) over five years due to Washington's request for sensitive data.
This move was revealed after a government memo from December was disclosed, which showed President Emmerson Mnangagwa deemed the arrangement was "unbalanced".
An official spokesman has since stated that the United States was requesting genetic material for research and profit while was unwilling to share the benefits from future treatments.
"We are forced to start the difficult and regrettable task of scaling back our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had provided more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for more dialogue to reach a deal acceptable to both sides so the country's vital HIV programme can proceed.
Broader Background
This development comes after a comparable case in Kenya, where a high court halted a similar deal with the US following concerns were raised about the safety of Kenyans' health data.
Since returning to office last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking government-to-government deals to enhance transparency and responsibility.
Based on reports, 16 nations in Africa have so far agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving HIV treatment through American-funded initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no equivalent guarantee of access to any medical innovations – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Effectively, our nation would provide the raw materials for medical research without any assurance that the resulting innovations would be available to our citizens if a new health crisis arise."
National Interest and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining frameworks previously established via the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with potential global health emergencies.
"This system is intended to guarantee that when a nation contributes its information, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to continued discussions with our US partners on how subsequent co-operation could be structured in a way that respects the independence and dignity of each country."
Health Experts Response
A leading public health body said it acknowledged the official position, but urged that talks should continue given that a large portion of the country's Aids initiatives relied on external financing.
"In cases where technical issues exist, including those relating to data governance or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it commented.
The situation emphasises the complex debate between receiving much-needed foreign assistance and protecting national sovereignty in an increasingly data-driven world.